XORTX Therapeutics Inc. is a pharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan (rare) disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) associated with coronavirus infection. Its three lead product candidates are XRx-008, for the treatment of ADPKD; XRx-101, to treat AKI associated with Coronavirus / COVID-19 infection, AKI and associated health consequences. In addition, XRx-225 is a pre-clinical stage program for type 2 diabetic nephropathy. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company is evaluating xanthine oxidase inhibitor candidates for the XRx-225 program to treat T2DN.
No company officers listed.
No insider trading activity.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.